The FDA this week released two warning letters recently sent to China-based contract manufacturer Huaian Zongheng Bio-Tech and New Jersey-based drug manufacturer Health Pharma for GMP violations. For Huaian Zongheng FDA inspectors said the firm released over-the-counter drugs without conducting identity or strength testing for each active ingredient. The firm also failed to test incoming components used to manufacture its drug products to determine their identity. While for Health Pharma, FDA inspectors, following a visit to the Rahway, New Jersey site last May and June, said the firm’s quality unit (QU) lacked the appropriate oversight of its drug manufacturing operations. Learn More